[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367376-105":59,"doc-detail-367376-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ddx54-downregulation-enhances-anti-pd1-therapy-in-immune-desert-lung-tumors-with-high-tumor-mutational-burden-research-article","DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden - Research article","","High tumor mutational burden (TMB-H) predicts responsiveness to immune checkpoint inhibitor (ICI) therapy, yet roughly 30% of cancers are immune-desert, lacking T cell infiltration despite high TMB-H. This study introduces a systems biology framework to identify immuno-oncotargets and validates them in models that convert immune-desert tumors into immune-inflamed tumors. DEAD-box helicases 54 (DDX54) is identified as a master regulator of immune escape, and DDX54 knockdown increases immune infiltration and improves sensitivity to anti-PD1 therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ddx54-downregulation-enhances-anti-pd1-therapy-in-immune-desert-lung-tumors-with-high-tumor-mutational-burden-research-article/367376/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ddx54-downregulation-enhances-anti-pd1-therapy-in-immune-desert-lung-tumors-with-high-tumor-mutational-burden-research-article/367376.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do immune-desert lung tumors resist anti-PD-1 therapy despite high TMB-H?","Question",{"text":112,"@type":113},"Immune-desert tumors lack T cell infiltration even when tumor mutational burden is high. The study attributes resistance to immune escape mechanisms that suppress infiltration into the tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is DDX54’s role in immune escape in immune-desert lung cancer?",{"text":117,"@type":113},"DDX54 is identified as a master regulator that promotes an immune-evasive tumor microenvironment by inducing CD38 and CD47 expression and inhibiting immune cell infiltration.",{"name":119,"@type":110,"acceptedAnswer":120},"How does DDX54 knockdown affect response to anti-PD-1 therapy?",{"text":121,"@type":113},"DDX54 knockdown increases infiltration of T cells, NK cells, and antitumor monocytes and sensitizes tumors to anti-PD-1 therapy, reprogramming immune-desert tumors toward an immune-inflamed state.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367376,1790198088,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  \nSYSTEMS BIOLOGY  \nDDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden  \nJeong-Ryeol Gonga,1, Jungeun Leea,1, Younghyun Hana, and Kwang-Hyun Choa,2 Affiliations are included on p. 12.  \nEdited by Carl June, University of Pennsylvania, Philadelphia, PA; received June 19, 2024; accepted February 25, 2025  \nHigh tumor mutational burden (TMB-H) is a predictive biomarker for the responsiveness of cancer to immune checkpoint inhibitor (ICI) therapy that indicates whether immune cells can sufficiently recognize cancer cells as nonself. However, about 30% of all cancers from The Cancer Genome Atlas (TCGA) are classified as immune-desert tumors lacking T cell infiltration despite TMB-H. Since the underlying mechanism of these immune-desert tumors has yet to be unraveled, there is a pressing need to transform such immune-desert tumors into immune-inflamed tumors and thereby enhance their responsiveness to anti-PD1 therapy. Here, we present a systems framework for identifying immuno-oncotargets, based on analysis of gene regulatory networks, and validating the effect of these targets in transforming immune-desert into immune-inflamed tumors. In particular, we identify DEAD-box helicases 54 (DDX54) as a master regulator of immune escape in immune-desert lung cancer with TMB-H and show that knockdown of DDX54 can increase immune cell infiltration and lead to improved sensitivity to anti-PD1 therapy.  \nDDX54 | immuno-oncotargets | tumor mutational burden | anti-PD1 therapy | systems biology  \nImmune checkpoint inhibitor (ICI) therapy has dramatically improved survival rates and induced sustainable long-term responses in many patients with various cancers that were previously untreatable (1, 2). Nevertheless, the efficacy of ICI therapy remains restricted to a minor subset of patients (3, 4). Furthermore, despite endeavors to augment its response rate through combination therapies, the success rate remains inadequate (5) . To address this problem, we sought to directly address the cause of the immune evasion mechanisms of cancer cells, rather than to induce only the activation of immune cells.  \nPrevious studies on the anticancer mechanisms of ICI therapy suggested that such ICI therapy could reinvigorate preexisting T cells in cancer tissue and that those T cells could induce cancer cell death. However, it was revealed that the T cells that infiltrated into cancer tissues had already been exhausted and could not be reinvigorated by ICI therapy due to epigenetic scarring ofT cells (6) . In addition, single-cell T cell receptor analysis revealed that in patients responsive to ICI therapy, expansion of newly infiltrated T cell clones is induced following ICI therapy, rather than expansion of preexisting T cell clones within the cancer tissues (7). Together, these suggest that to improve the efficacy of ICI therapy, we need to block the mechanisms that inhibit T cell infiltration into cancer tissues and induce the expansion of infiltrated novel T cell clones.  \nImmune cells recognize cancer mutations as non-self-antigens, so accumulations of immune cells can facilitate infiltration ofT cells and thereby enhance the efficacy of ICI therapy. From this, a high tumor mutation burden (TMB-H) has been approved by the US Food and Drug Administration (FDA) as a favorable predictive biomarker for ICI therapy efficacy across various cancers (8, 9). However, despite the role of tumor mutation as a recognizable marker of cancer to ICI therapy, its effectiveness in identifying patients who might respond to ICI therapy is still limited. This limitation might arise from the fact that the antigen-processing procedure of cancer mutations for immune cell recognition and the subsequent clearance of recognized antigens are both long and complicated processes. Such mechanisms aim to prevent any possible self-damage that might be caused by the activation of aberrant immune cells. Interesting","cbCaio3gXUZanVbo","https://ap.wps.com/l/cbCaio3gXUZanVbo","pdf",11465648,12,"English","# Significance\n# Abstract and study rationale\n## Immune-desert tumors and TMB-H\n## Systems biology framework and target identification\n# Mechanistic focus on DDX54\n## Immune infiltration and immune-evasive TME\n## Effects of DDX54 knockdown with anti-PD-1","[{\"question\":\"Why do immune-desert lung tumors resist anti-PD-1 therapy despite high TMB-H?\",\"answer\":\"Immune-desert tumors lack T cell infiltration even when tumor mutational burden is high. The study attributes resistance to immune escape mechanisms that suppress infiltration into the tumor microenvironment.\"},{\"question\":\"What is DDX54’s role in immune escape in immune-desert lung cancer?\",\"answer\":\"DDX54 is identified as a master regulator that promotes an immune-evasive tumor microenvironment by inducing CD38 and CD47 expression and inhibiting immune cell infiltration.\"},{\"question\":\"How does DDX54 knockdown affect response to anti-PD-1 therapy?\",\"answer\":\"DDX54 knockdown increases infiltration of T cells, NK cells, and antitumor monocytes and sensitizes tumors to anti-PD-1 therapy, reprogramming immune-desert tumors toward an immune-inflamed state.\"}]","DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden - Research article | PDF",1790170521,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3e60bcb211073549f8cf7f508091230.webp",983,1316,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc6e0210e612ed2b5afde67465b7889f.webp",982,1315,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/351a406c7104893d5bb93f5869c25d8f.webp",981,1313,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdb12aced66b47d30d05271e2883fe97.webp",980,1312]